A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a potential therapeutic target. Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was incorporated into a modified chemotherapy backbone to achieve complete remission prior to stem cell transplant. Treatment was well tolerated and she had undetectable MRD prior to a matched allogeneic stem cell transplant and remained in remission at day +100.
INTRODUCTION
Despite advances in the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), children and young adults who present with clinical and molecular features of high-risk disease remain challenging to cure. Since first described by the Dutch (DCOG) and German (COALL) pediatric cooperative groups in parallel with the St. Jude group, approximately 15% to 20% of patients with BCP-ALL have been found to have gene expression profiles similar to those observed with the BCR-ABL1 fusion, but lack the sentinel t(9;22)(q34;q11.2). 1, 2 Termed "BCR-ABL1-like," affected patients present with National Cancer Institute high-risk features, demonstrate persistent postinducAbbreviations: ALL, Acute lymphoblastic leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Münster; BID, "bis in die"/twice a day; CLIA, Clinical Laboratory Improvement Amendments; COG, Children's Oncology Group; DNA, Deoxyribonucleic acid; GIMEMA, Gruppo Italiano Malattie e Matologiche dell'Adulto (Italian Group for Adult Hematologic Diseases); MRD, Minimal residual disease; RNA, Ribonucleic acid; TKI, Tyrosine kinase inhibitor tion minimal residual disease (MRD), and harbor a range of genetic alterations that activate kinase signaling. 3, 4 In case reports where BCR-ABL1-like lesions have been identified early in treatment, imatinib, a tyrosine kinase inhibitor (TKI) targeted against ABL1, ABL2, PDGFRB, and other lesions, has been successfully used to treat refractory disease. 5 Because BCR-ABL1-like BCP-ALL is more prevalent in adolescents and young adults, this patient population has been identified to potentially benefit greatly from targeted therapies. 6, 7 In the current treatment era, there are few guidelines regarding the management of BCR-ABL1-like leukemias, including which methods are recommended to identify, characterize, and validate novel lesions, when to assess response, or how to integrate TKIs safely into combination therapy. We present a case in which we identified and validated a 
Leukemia DNA sequencing methods
Because persistent MRD beyond day 29 of induction therapy is highly associated with relapse, we evaluated whether our patient had a BCR-ABL1-like targetable lesion through an iterative cascade of molecular testing. 8 As part of NCT02105545, low-density array (LDA) screening, deep gene and ribonucleic acid (RNA) sequencing was done to further evaluate for a BCR-ABL1-like lesion. 4 Using the gene expression assay via the LDA card, we found a gene signature consistent with BCR-ABL1-like BCP-ALL with a high expression of CRLF2. 3 We next undertook deep sequencing of over more than 400 cancer-relevant genes (Ion Ampliseq Comprehensive Cancer Panel, Thermo Fisher) and identified a novel F694L mutation in JAK2, which specifically involved a T to C transition in exon 16 at base-pair locus 5078393, and a cluster of mutations (p.Cys119_Ile121delinsTrpGlyLeu) in IKZF1 in the diagnostic sample (Fig. 2) . These genomic variants were nearly undetectable in the day 29 postinduction sample, showing that they were restricted to the lymphoblast population affected by chemotherapy. Unbiased RNA sequencing confirmed that the JAK2 mutation was present in expressed messenger RNA. Our findings were validated by Clinical Laboratory Improvement Amendments (CLIA)-approved Foundation One Heme (Cambridge, MA), confirming the presence of the molecular variants, in addition to an IGH-CRLF2 translocation (Fig. 2) . Using CLIAapproved sample acquisition, polymerase chain reaction, and Sanger sequencing techniques, TriCore Reference Laboratories validated the F694L JAK2 mutation in the presentation specimen (Fig. 2) . At the recommendation of our multidisciplinary molecular tumor board, the patient was removed from protocol therapy and the JAK2 inhibitor ruxolitinib was integrated into conventional cytotoxic therapy, with close monitoring for adverse events.
Because there is no precedent for the incorporation of ruxolitinib into dose-intensified conventional therapy, we chose to use 40 mg/m 2 /day BID ("bis in die"/twice a day) for 2 weeks on, 2 weeks off, based on the safety phase findings of COG ADVL1011. 6 It was delayed until interim maintenance as the JAK2 mutation was confirmed in two CLIA labs and authorization was obtained from insurance. Our patient had expected and manageable toxicities related to the consolidation, interim maintenance, and delayed intensification phases of COG AALL1131. She also experienced delays in treatment related to persistent thrombocytopenia and neutropenia, which were attributable to the inclusion of ruxolitinib to her treatment schedule.
Ruxolitinib was held when the absolute neutrophil count < 750 or platelets < 75,000. Our patient's MRD continued to decline during these phases of therapy (Fig. 1) . There was a small transient rise in the MRD level during interim maintenance, which was felt to be due to several held doses due to admission for febrile neutropenia. When her MRD had diminished to <0.01%, she was taken to an allogeneic transplant with a fully matched sibling. Molecular remission was unable to be ascertained due to the undetectable level of blasts. She was found to be 100% engrafted with donor cells at day 100 post-transplant. 16 . The V617F mutation site is commonly identified in patients with myelodysplastic disorders, while the F694L site has not been previously described to occur in ALL. (B) The F694L mutation is predicted to interfere with signal transduction in the location shown by the solid arrow 18 
DISCUSSION
Among the many prognostic factors that have been developed to predict relapse, the persistence of MRD has emerged as one of the strongest and most reliable. [8] [9] [10] The international BFM and GIMEMA (Gruppo Italiano Malattie e Matologiche dell'Adulto/Italian Group for Adult Hematologic Diseases) cooperative groups reported that children and adults with day 29 MRD levels of greater than 1% were at a very high risk of relapse. In the International BFM study, patients who had MRD levels of 10 −2 or greater had five-to ten-fold higher relapse rates at 3 years (39%-86%). 9 In the GIMEMA study, the probability of relapse at 2 years for MRD-positive patients at preconsolidation was 81.5% versus 38.9% for MRD-negative patients. 11 In the last COG high-risk ALL study, the presence of MRD at the end of consolidation had a disease free survival (DFS) of only 39% versus 79% in patients without MRD. 8 Because our patient had postinduction MRD that was rising, we were compelled to augment her care with a therapeutic approach that might prevent relapse.
The utilization of targeted therapies provides a novel opportunity to prevent relapsed disease, but targets must be identified and implemented early in the treatment course to be of benefit. Using an iterative approach to our patient's molecular diagnostics, we identified and characterized a novel JAK2 lesion in a highly conserved region of the enzyme that provided an opportunity to select a TKI for incorporation into our patient's treatment regimen. 12 Targeted therapies as single agents against kinome deregulated leukemias are alone insufficient for cure in the relapsed setting, calling for a rapid and accurate identification of lesions. 13, 14 In the setting of BCR-ABL-positive leukemias, the introduction of integrated TKI therapies, starting during induction, has achieved remarkable treatment success. 15, 16 Preclinical data have demonstrated that ruxolitinib is effective in BCR-ABL1-like ALL. 17 The pending COG study AALL1521 will investigate whether adding a JAK2 inhibitor to chemotherapy for patients with CRLF2-rearranged or JAK-mutated ALL will improve outcome. Our findings demonstrate the promise of genome sequencing in acute lymphoblastic leukemia in a patient who demonstrated persistent high MRD without targeted therapy. With the inclusion of a lesionspecific TKI into a dose-intensified, COG-modified BFM regimen, she achieved an MRD-negative remission, and remains in first complete response for more than 100 days after transplant.
